MOTS-c: the mitochondrial peptide and what the evidence shows

A peptide with an unusual address

Almost every peptide in this category is a version of something your pituitary or your gut already makes, encoded in the nucleus like the rest of your proteins. MOTS-c is not. It is a 16 amino acid peptide encoded within the mitochondrial 12S ribosomal RNA gene, in the separate loop of DNA your mitochondria carry.

Lee and colleagues described it in Cell Metabolism in 2015 and gave it a name that states the hypothesis: mitochondrial open reading frame of the 12S rRNA type-c. The finding that made it interesting was not that it existed, but that it appeared to act outside the mitochondrion, influencing metabolism in tissues at a distance.

That reframes mitochondria as something other than passive power plants. If they encode signals, they participate in deciding how the rest of the body handles energy, which is a more interesting claim than anything on a supplement label.

What the original research found

In the 2015 work, MOTS-c interfered with the folate and methionine cycle, which raised the intracellular level of a purine intermediate and in turn activated AMPK. AMPK is the sensor that responds to low cellular energy, and it is the pathway exercise and metformin converge on, so this is a credible place for a metabolic peptide to act.

The functional results in mice followed that mechanism. Treated animals showed improved insulin sensitivity, and mice fed a high fat diet gained less weight and resisted the insulin resistance that diet normally produces. Muscle glucose handling improved rather than appetite falling, which is a different pattern from a GLP-1 medication.

Later work from the same group and others found that MOTS-c moves into the nucleus under metabolic stress and influences gene expression there, and that circulating levels decline with age in humans.

• Encoded in mitochondrial DNA, 16 amino acids, described by Lee and colleagues in Cell Metabolism, 2015.
• Acts through the folate and methionine cycle to activate AMPK, the cellular energy sensor.
• In mice: improved insulin sensitivity and reduced diet-induced obesity and insulin resistance.
• In humans: circulating levels rise with acute exercise and decline with age.

The exercise connection, and what it does and does not prove

Reynolds and colleagues reported in Nature Communications in 2021 that MOTS-c levels in skeletal muscle and in blood rose after exercise in humans, and that MOTS-c administration improved physical performance in mice across age groups. The human half of that paper is observational: exercise raises the peptide.

It is tempting to run that logic backwards and conclude that raising the peptide produces the benefits of exercise. That inference is not supported. A signal that rises during a stress response is not automatically the cause of the adaptation, and plenty of molecules that mark exercise have failed to reproduce it when given.

A separate line of evidence looks at genetics. Fuku and colleagues studied a mitochondrial variant that changes the MOTS-c sequence and found it associated with type 2 diabetes risk in a Japanese population, with an interaction with physical activity. Association studies in one population are a reason to keep investigating, not a reason to conclude.

The honest state of human evidence

There are no published randomized controlled trials of administered MOTS-c in humans yet. The clinical literature so far is animal work, mechanistic cell work, observational human measurements and case level reports, which is a normal early stage for a molecule this young and also a real limit on what anyone can promise.

That absence has a consequence worth stating plainly: nobody can tell you the effect size in a person, the duration of benefit, or the long term safety profile, because the studies that would establish those have not been run. A peptide encoded by your own mitochondria is not automatically safe to inject at a supraphysiologic level, and the fact that a molecule is endogenous tells you nothing about the safety of the amount.

This is different from the situation with tirzepatide or semaglutide, where large phase 3 trials with published outcomes exist. It is worth understanding which category a therapy sits in before you decide it belongs in your plan.

How Baseline treats it

MOTS-c is catalogued as a short add-on alongside a metabolic cycle rather than as a standalone plan, and it is deliberately time limited. Ordering status is shown on its therapy page. The reasoning is that a therapy without trial evidence should be tested against your own numbers over a defined window, not continued indefinitely on the strength of how you feel.

That means we recommend fasting insulin, fasting glucose and HbA1c before you start and after you finish, along with weight and waist measurement. If nothing moved, that is useful information and a reason to stop rather than to increase.

The other honest framing: the interventions with the strongest metabolic evidence are still training, sleep, alcohol reduction and the GLP-1 class where appropriate. MOTS-c is an addition to a plan that already does those things, not a substitute for them, and a provider in our network decides whether it belongs in your case at all.

References

1. Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 2015
2. Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications, 2021
3. Fuku N, et al. The mitochondrial-derived peptide MOTS-c: a player in exceptional longevity? Aging Cell and related work on the m.1382A>C variant and type 2 diabetes risk
4. Kim SJ, et al. Mitochondrially derived peptides as novel regulators of metabolism. Journal of Physiology, review
5. Biomarker hub: Fasting insulin, HOMA-IR and HbA1c
6. Tool: HOMA-IR calculator